TIDMYGEN
Yourgene Health PLC
12 October 2020
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Elucigene DPYD tests to be used routinely in Wales
Wales is first UK nation to offer DPYD screening to patients
undergoing chemotherapy
DPYD tests screen patients to identify risk of severe side
effects from certain chemotherapy treatments
Manchester, UK - 12 October 2020: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces its oncology
product, Elucigene DPYD test, is now being used in Wales to
routinely screen all cancer patients prior to the start of
treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to
identify the risk of severe side effects.
Wales is the first nation in the UK to implement this screening
programme and offer the DPYD test to all patients, with over 400
samples already taken and 6% of patients coming back positive. All
Wales Medical Genomics Service (AWMGS), which provides specialist
genetic services to individuals with, or concerned about rare
genetic conditions, commenced a pilot phase earlier this year which
was successful, leading to the launch of the service this week. It
has led to all health boards across Wales routinely offering the
DPYD test to cancer patients, of which Yourgene is the sole
provider.
Elucigene DPYD is a simple-to-use genotyping test that can
identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD)
deficiency, which can cause severe and sometimes lethal side
effects in patients being treated with chemotherapeutic drug
5-Fluorouracil (5-FU), commonly used in the treatment of colon,
oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU
is metabolized by the DPD enzyme which is encoded by the DPYD
gene.
Yourgene will be providing the Elucigene DPYD tests to screen
for approximately 200 patients each month for the next year. If
2,400 patients are screened, at the positive rate of 6% continues,
we anticipate 144 cancer patients will be prevented from having
toxic chemotherapy reactions.
Lyn Rees, CEO of Yourgene, commented: "It is fantastic to see
this form of personalised medicine implemented across Wales,
allowing the quality of care for cancer patients to improve,
ultimately saving lives. Yourgene is proud to be sole supplier of
DPYD so soon after its launch in September 2019 and looks forward
to similar schemes being rolled out across the UK."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which
develops and commercialises genetic products and services. The
group works in partnership with global leaders in DNA technology to
advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, for reproductive health and
molecular genetics. The Group's products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, male infertility tests and genetic disease tests.
Yourgene's commercial footprint is already established in the UK,
Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene is also extending its genetic
testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in
Taipei and Singapore, and is listed on the London Stock Exchange's
AIM market under the ticker "YGEN". For more information, visit
www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAKENELEEFFA
(END) Dow Jones Newswires
October 12, 2020 02:00 ET (06:00 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jan 2025 to Feb 2025
Premaitha (LSE:NIPT)
Historical Stock Chart
From Feb 2024 to Feb 2025
